A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

NCT03131687 on ClinicalTrials.gov · last registry update 2019-08-20

An unusually large phase 2: 318 participants, more than double the 110 typical for the stage. The sponsor logged completion for 1 August 2018. Primary outcome, as filed: Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) Bayesian Dose Response. tirzepatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 318
Started: 2017-05-24
Primary completion: 2018-08-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) Bayesian Dose Response

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.